85666-17-7
85666-17-7
Chemical Structure
Furegrelate sodium
Synonym(s): U-63557A
- CAS No.: 85666-17-7
- Formula:C15H10NNaO3
- Molecular Weight:275.23
IUPAC Name: sodium 5-(pyridin-3-ylmethyl)benzofuran-2-carboxylate
InChIKey: XBTIPIZROJAKOJ-UHFFFAOYSA-M
SMILES: O=C(C1=CC2=CC(CC3=CC=CN=C3)=CC=C2O1)O[Na]
Biological Activity: Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Furegrelate sodium | 99.69% | Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Furegrelate sodium (Standard) | ≥98% | Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Furegrelate | Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
α-Amylase-IN-3 | 99.49% | α-Amylase-IN-3 (Compound 4) is the inhibitor for α-Amylase, AChE and AChE with IC50s of 18.04 μM, 21.04 μM and 22.2 μM, respectively. α-Amylase-IN-3 exhibits antioxidant activity. α-Amylase-IN-3 can be used in research of diabetes and oxidative stress associated disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OKY-1581 | OKY-1581 is a potent, orally active and selective thromboxane A2 synthase inhibitor. OKY-1581 inhibits TXA2 synthesis and reduces the generation of its stable metabolite TXB2. OKY-1581 shifts arachidonic acid (MCE HY-109590) metabolism toward the production of prostaglandin E, prostaglandin F and 6-keto-prostaglandin F1α. OKY-1581 modulates the TXA2 / PGI2-related eicosanoid balance and inhibits arachidonic acid-induced platelet aggregation without directly inhibiting the cyclooxygenase step. At high oral doses, OKY-1581 also enhances hepatic peroxisomal β-oxidation and reduces serum triglyceride and cholesterol levels. OKY-1581 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage by reducing TXA2-related vasoconstrictive signaling. OKY-1581 can be used in studies of atherosclerosis, cerebral vasospasm after subarachnoid hemorrhage and cardiovascular diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ethyl 5-piperazin-1-ylbenzofuran-2-carboxylate | 99.88% | Ethyl 5-piperazin-1-ylbenzofuran-2-carboxylate is a drug intermediate for synthesis of various active compounds. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-(1-Piperazinyl)-2-benzofurancarboxylic acid ethyl ester dihydrochloride hydrate | 99.69% | 5-(1-Piperazinyl)-2-benzofurancarboxylic acid ethyl ester (Ethyl 5-(piperazin-1-yl)benzofuran-2-carboxylate) dihydrochloride hydrate is a drug intermediate for synthesis of various active compounds. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benzyl nicotinate (Standard) | ≥98% | Benzyl nicotinate (Standard) is the analytical standard of Benzyl nicotinate. This product is intended for research and analytical applications. Benzyl nicotinate is a vasodilator that increases skin oxygenation levels by increasing skin blood flow. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ethyl 5-(piperazin-1-yl)benzofuran-2-carboxylate hydrochloride | 99.28% | Ethyl 5-(piperazin-1-yl)benzofuran-2-carboxylate hydrochloride is a drug intermediate for synthesis of various active compounds. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dibenzo[b,d]furan-2,8-dicarboxylic acid | Dibenzo[b,d]furan-2,8-dicarboxylic acid is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MAO-B-IN-46 | MAO-B-IN-46 (Compound 16) is a selective hMAO-B inhibitor (IC50: 26.8 nM), with weak activity against hMAO-A (IC50: 7.2054 μM). MAO-B-IN-46 (Compound 8) also acts as an α-amylase inhibitor (IC50: 19.46 μM). MAO-B-IN-46 exhibits certain neuroprotective effects and shows no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS free radicals, with IC50 values of 17.86 μM and 17.71 μM, respectively. MAO-B-IN-46 can be used in the research of neurodegenerative diseases such as Parkinson's disease, diabetes, and diseases related to oxidative stress resistance. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Methyl 5-nitro-2-benzofurancarboxylate (Standard) | ≥98% | Methyl 5-nitro-2-benzofurancarboxylate (Standard) is the analytical standard of Methyl 5-nitro-2-benzofurancarboxylate. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gorman RR, et al. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins. 1983 Aug;26(2):325-42. [Content Brief]
- [2]. Hirenallur-S DK, et al. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2(2):193-200. [Content Brief]
